Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.67 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.45 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6949108 | 0.85 | ESR2 (0.62) | ESR2PTPN5FFAR1AKR1B1MME | |
| SCHEMBL31410710 | 0.83 | ESR2 (0.76) | ESR2PTPN5FFAR1AKR1B1PPARG | |
| SCHEMBL31772593 | 0.83 | ESR2 (0.59) | ESR2PTPN5FFAR1AKR1B1MME | |
| SCHEMBL31124937 | 0.83 | ESR2 (0.59) | ESR2PTPN5FFAR1AKR1B1MME | |
| SCHEMBL29170999 | 0.83 | ESR2 (0.59) | ESR2PTPN5FFAR1AKR1B1MME | |
| SCHEMBL3169219 | 0.83 | ESR2 (0.59) | ESR2PTPN5FFAR1AKR1B1MME | |
| SCHEMBL357 | 0.83 | ESR2 (0.59) | ESR2PTPN5FFAR1AKR1B1MME | |
| SCHEMBL360601 | 0.83 | ESR2 (0.59) | ESR2PTPN5FFAR1AKR1B1MME | |
| SCHEMBL7867991 | 0.83 | ESR2 (0.59) | ESR2PTPN5FFAR1AKR1B1MME | |
| SCHEMBL9542596 | 0.83 | ESR2 (0.59) | ESR2PTPN5FFAR1AKR1B1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111454148-A | Telmisartan impurity compound and preparation method thereof | 东南大学 | 2020-07-28 | — | — | CN | claimed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| CN-115197096-B | Synthesis method of valsartan intermediate | 山东新时代药业有限公司 | 2025-09-05 | — | — | CN | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119365467-A | Aza-tetraepoxy aza compounds and uses thereof | 基因泰克公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2024-11-07 | — | — | US | disclosed |
| CN-118359555-A | Preparation method of valsartan intermediate | 南京一心和医药科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2000078726-A1 | IMIDAZOLINE DERIVATIVES FOR THE TREATMENT OF DIABETES, ESPECIALLY TYPE II DIABETES | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-5874593-A | SULFUR CONTAINING AMIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-02-23 | — | — | US | disclosed |
| US-5587390-A | Imidazole derivatives having a II antagonist activity | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1996-12-24 | — | — | US | disclosed |
| EP-0654030-B1 | IMIDAZOLE DERIVATIVES HAVING ANGIOTENSIN II ANTAGONIST ACTIVITY | LUSO FARMACO INST (IT) | 1996-12-18 | — | — | EP | disclosed |
| EP-0711762-A1 | PROCESS FOR PRODUCING TETRAZOLE COMPOUND AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| WO-1994003449-A1 | IMIDAZOLE DERIVATIVES HAVING A II ANTAGONIST ACTIVITY | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1994-02-17 | — | — | WO | disclosed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | ESR2 1635/4885PTPN5 1346/4885FFAR1 3738/4885 |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | ESR2 1635/4885PTPN5 1346/4885FFAR1 3738/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | ESR2 1101/4885PTPN5 1211/4885FFAR1 1952/4885 |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | ESR2 1635/4885PTPN5 1346/4885FFAR1 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.